🚨 Wow! #ASCO25@ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert
The most impressive myeloma abstract at #ASCO25
Outstanding longterm efficacy with cilta-cel CAR-T.
5 year survival rate 50%
5 year PFS rate of 33%
Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete@NoopurRajeMD @TomBmt133 @YiLinMDPhD@DMadduri@bhemato@BerdejaJesus
https://t.co/YiHsGhZ3cw
Magrolimab once showed promise in TP53-mutated AML, but recent data didn’t meet the mark, and development has been halted. A tough reminder of the challenges in translating early hope into clinical success. #AML https://t.co/RRGbYHjakf
First report of the Ph 2 trial of the CLIA regimen in pts w/ R/R #AML: CR/CRi of 49% & median OS of 12 months in pts who received it as 1st salvage rx. Data provides tolerable & effective backbone upon which to build combination strategies @JournalCancer
https://t.co/EHzqqzGLtc
Hematology Post Doc Research Fellow Job Opening @washumedicine St. Louis, MO
Info/Apply HERE: https://t.co/MAVczqUL9I
Lab Info: https://t.co/lYArxPl4f4
#InsideTheMatch
NGS MRD (clonoSEQ) is the most sensitive and specific MRD assay in Ph+ #ALL. Therapeutic decision-making should be based on NGS rather than PCR for BCR::ABL1
@NicholasShortMD of @MDAndersonNews#Leukemia
https://t.co/rlZ0aMlGll
#leusm
Sensational multicenter collaborative work presented by Yale fellow @tariqkewan on the clinical implications of tp53 mutation in patients with MDS!! @YaleCancer@Dr_AmerZeidan#ASH23
I’m at the point where I will rather quit than do @ABIMcert Longitudinal Knowledge Assessment (LKA) and try to keep ABIM certification active.
It’s interfering with patient care and research for me. And I’m getting the myeloma questions wrong. Useless.
@Rfonsi1#MedTwitter